Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This clinical trial is a Phase 1-2, open-label, sequential-group, dose-escalation and
cohort-expansion study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and
antitumor activity of Zotatifin (eFT226) in subjects with selected advanced solid tumor
malignancies. The study will evaluate weekly 1-hour intravenous (IV) administration of
Zotatifin (eFT226). Treatment and study subject evaluations will be performed in 21 day
cycles.